These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19118225)

  • 21. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer.
    Dai F; Liu L; Che G; Yu N; Pu Q; Zhang S; Ma J; Ma L; You Z
    BMC Cancer; 2010 May; 10():220. PubMed ID: 20487543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of tumor-infiltrating dendritic cells in human non-small cell lung carcinoma in relation to apoptosis.
    Kurabayashi A; Furihata M; Matsumoto M; Hayashi H; Ohtsuki Y
    Pathol Int; 2004 May; 54(5):302-10. PubMed ID: 15086834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Turley H; Talks K; Pezzella F; Gatter KC; Harris AL
    Br J Cancer; 2001 Sep; 85(6):881-90. PubMed ID: 11556841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
    Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
    Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.
    Graziano SL; Tatum AH; Gonchoroff NJ; Newman NB; Kohman LJ
    Clin Cancer Res; 1997 Jan; 3(1):87-93. PubMed ID: 9815542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
    Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y
    Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
    Kojima H; Shijubo N; Yamada G; Ichimiya S; Abe S; Satoh M; Sato N
    Cancer; 2005 Oct; 104(8):1668-77. PubMed ID: 16116610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer.
    Mino N; Takenaka K; Sonobe M; Miyahara R; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Mar; 95(3):250-7. PubMed ID: 17323339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.
    Wada N; Zaki MA; Hori Y; Hashimoto K; Tsukaguchi M; Tatsumi Y; Ishikawa J; Tominaga N; Sakoda H; Take H; Tsudo M; Kuwayama M; Morii E; Aozasa K;
    Histopathology; 2012 Jan; 60(2):313-9. PubMed ID: 22211289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer.
    Ilie M; Hofman V; Ortholan C; Bonnetaud C; Coëlle C; Mouroux J; Hofman P
    Cancer; 2012 Mar; 118(6):1726-37. PubMed ID: 21953630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer.
    Liu PL; Tsai JR; Chiu CC; Hwang JJ; Chou SH; Wang CK; Wu SJ; Chen YL; Chen WC; Chen YH; Chong IW
    Mol Carcinog; 2010 Oct; 49(10):874-81. PubMed ID: 20607726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.
    Chen JJ; Yao PL; Yuan A; Hong TM; Shun CT; Kuo ML; Lee YC; Yang PC
    Clin Cancer Res; 2003 Feb; 9(2):729-37. PubMed ID: 12576442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node.
    Saintigny P; Kambouchner M; Ly M; Gomes N; Sainte-Catherine O; Vassy R; Czernichow S; Letoumelin P; Breau JL; Bernaudin JF; Kraemer M
    Lung Cancer; 2007 Nov; 58(2):205-13. PubMed ID: 17686546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
    Al-Shibli KI; Donnem T; Al-Saad S; Persson M; Bremnes RM; Busund LT
    Clin Cancer Res; 2008 Aug; 14(16):5220-7. PubMed ID: 18698040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis.
    Meyer M; Huaux F; Gavilanes X; van den Brûle S; Lebecque P; Lo Re S; Lison D; Scholte B; Wallemacq P; Leal T
    Am J Respir Cell Mol Biol; 2009 Nov; 41(5):590-602. PubMed ID: 19244203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma.
    Marrogi AJ; Travis WD; Welsh JA; Khan MA; Rahim H; Tazelaar H; Pairolero P; Trastek V; Jett J; Caporaso NE; Liotta LA; Harris CC
    Clin Cancer Res; 2000 Dec; 6(12):4739-44. PubMed ID: 11156228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
    Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.